valgansiklovir治疗CMV视网膜炎疗效怎样？

Valganciclovir hydrochloride (valganciclovir hydrochloride) is a prescription antiviral drug. In adults, valganciclovir hydrochloride is used: to treat cytomegalovirus (CMV) retinitis in people with immunodeficiency syndrome (AIDS). When the CMV virus infects the eye, it is called CMV retinitis. If CMV retinitis is not treated, blindness may result. To prevent CMV disease in people who have received a kidney, heart, or kidney-pancreas transplant and are at high risk for CMV disease. Valganciclovir hydrochloride (valganciclovir) is the prodrug of ganciclovir and is rapidly converted into ganciclovir after oral administration. Valganciclovir hydrochloride (valganciclovir, trade name: Valganciclovir, etc.) is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients. Valganciclovir needs to be taken long-term because it only suppresses the infection, not cures it. So, what is the efficacy of valganciclovir hydrochloride in the treatment of CMV retinitis?

Clinical studies of valganciclovir hydrochloride tablets (valgansiklovir) in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets (valgansiklovir) and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablets (valgansiklovir) group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week four was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with valgancilovir hydrochloride tablets (valgansiklovir) 900 mg daily. In patients who received induction therapy with valganciclovir or intravenous ganciclovir followed by maintenance therapy with valganciclovir, the mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days, respectively.